Global pharmaceutical R&D is consolidating around a single compute layer: NVIDIA's BioNeMo. Major drugmakers across North America and Europe are restructuring pipelines around the platform, moving from isolated AI experiments to production-grade dependencies.1
Novo Nordisk — Europe's most valuable company by market cap as of 2025 — saw its stock rise 25% over 30 days following strong Q1 2026 earnings tied to a leaner, licensing-first strategy.1 The Danish pharma giant closed its internal cell therapy unit and outsourced Parkinson's disease development to Cellular Intelligence, an AI-platform company.1 The move signals that even the world's largest drug developers now treat external AI infrastructure as more reliable than internal labs.
US-based Eli Lilly is also rebuilding R&D around AI-native workflows, joining Novo Nordisk in treating foundation models as operational tools rather than research experiments.1
Five new platforms launched in rapid succession: Basecamp Research's EDEN, Boltz Lab, Owkin's OwkinZero, Edison Scientific's Kosmos, and a new Natera offering.1 The clustering reflects productization, not experimentation. NVIDIA sits at the compute layer beneath all of them — mirroring AWS's role in cloud software globally.
BioNeMo provides pre-trained biological foundation models covering proteins, DNA, and small molecules. Pharmaceutical teams use it to accelerate target identification and molecular generation without building models from scratch.
Each new platform carves a vertical niche: Owkin's OwkinZero targets federated learning across hospital networks — a model with particular appeal in Europe's fragmented health data landscape. Basecamp Research's EDEN draws on biodiversity-derived molecular datasets. Both rely on NVIDIA compute underneath.
The new deal structure emerging in biotech — licensing AI platform access rather than acquiring companies or building internal teams — keeps capital flexible and shifts R&D risk to platform providers. It is a model with global implications for how pharmaceutical innovation is financed and structured.
Foundation models are no longer a differentiator. Competitive advantage now sits in proprietary datasets, domain-specific fine-tuning, and clinical partnerships built on top of shared compute.
